March 22, 2006 (PRIMEZONE) -- Pacific Energy Resources Ltd. (TSX:PFE) (the "Company") is pleased to announce that effective March 21, 2006, its shares of common stock commenced trading on the Toronto Stock Exchange under the …
Read on... Acceleron Pharma Inc. (XLRN) has priced an underwritten public offering of 5.40 million shares of common stock at a price of $37.00 each. The gross proceeds from the offering are estimated to be about $200 million. In connection …
Pfizer Inc.’s PFE shares were up in pre-market trading on the company’s first quarter results. While the company's earnings per share of 67 cents were well above the Zacks Consensus Estimate of 55 cents, revenues of $13 billion …
Dr. Freda C. Lewis-Hall, M.D., is Executive Vice President, Chief Medical Officer of the Company. Dr. Lewis-Hall was Senior Vice President, Chief Medical Officer from May 2009 until December 2010. Previously, she was Chief Medical …
MGM stock closed up 31¢ to $9. A recurring complaint from people participating in the auction of PFE has been the difficulty of getting detailed financial data on the company, and that seems to have been an issue over the weekend as …
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, …
The New York Stock Exchange, Nasdaq and CME Group in Chicago closed Monday. Trading on the NYSE was last closed on Sept. 11, 2001. The last time it closed for a weather event was in 1985, when Hurricane Gloria hit the East …
Pfizer (PFE) is doing the same thing as AZ. After announcing it will close a New London, Conn., R&D site and consolidate operations at nearby Groton, the company will expand operations in Wuhan, China, where 200 jobs will be added, …
SAO PAULO Pfizer Inc has agreed to exit Laboratório Teuto Brasileiro SA for a token amount after failing to find a buyer for the 40 percent stake it held in the Brazilian generic drugmaking joint venture, two people with knowledge of the …
Along with approval for use in combination with fulvestrant, Verzenio has the unique indication (relative to key competitors Pfizer’s (PFE) Ibrance and Novartis’s (NVS) Kisqali) for use as monotherapy after endocrine therapy and chemotherapy …